Atopic dermatitis (AD) is a common chronic inflammatory skin condition in pediatric patients. Probiotics have been proposed as a potential adjunctive therapy for AD because of anti-inflammatory effects and can alleviate clinical symptoms of atopic dermatitis (AD) in children. However, the effectiveness of probiotic supplementation in pediatric patients with AD remains controversial.This study aimed to evaluate the clinical efficacy of probiotics  for  AD in children. METHODOLOGY : We collected studies from several databases, including Pubmed, Cochrane, and ScienceDirect that were published from 2014 to 2024 with keywords “Atopic Dermatitis” OR “Eczema” AND “Pediatric” OR “Child” AND “Probiotic” OR “Lactobacillus” OR “Bifidobacterium” AND “Randomized Controlled Trial” OR “Clinical Trial”. Studies were assessed using Newcastle-Ottawa Scale (NOS). We performed a meta-analysis using a random-effect model in RevMan 5.4 with a 95% Confidence Interval (CI). RESULT: A total of 3 published studies with a total number of 300 patients with Atopic Dermatitis (AD) were included. Most studies were concluded to have a low risk of bias based on NOS assessment. The pooled analysis showed there was significant improvement in SCORAD [-7.04(-14.44 to 0.37) 95% CI, p-value = 0.008 I2= 79%] in treatment of probiotic.  However, the funnel plot showed an symmetrical figure, indicating low publication bias  CONCLUSION : Multistrain probiotic intervention was effective in reducing SCORAD index so it can reduce the rate of atopic dermatitis and promising therapy for Atopic Dermatitis (AD).